Vaniqa is a drug owned by Skinmedica Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 15, 2014. Details of Vaniqa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5648394 | Topical composition for inhibiting hair growth |
Jul, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Vaniqa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vaniqa's family patents as well as insights into ongoing legal events on those patents.
Vaniqa's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vaniqa's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 15, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vaniqa Generics:
There are no approved generic versions for Vaniqa as of now.
About Vaniqa
Vaniqa is a drug owned by Skinmedica Inc. It is used for treating excessive female facial hair. Vaniqa uses Eflornithine Hydrochloride as an active ingredient. Vaniqa was launched by Skinmedica in 2000.
Approval Date:
Vaniqa was approved by FDA for market use on 27 July, 2000.
Active Ingredient:
Vaniqa uses Eflornithine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Eflornithine Hydrochloride ingredient
Treatment:
Vaniqa is used for treating excessive female facial hair.
Dosage:
Vaniqa is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 13.9% | CREAM | Discontinued | TOPICAL |